英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
abnegaci查看　abnegaci　在百度字典中的解释百度英翻中〔查看〕
abnegaci查看　abnegaci　在Google字典中的解释Google英翻中〔查看〕
abnegaci查看　abnegaci　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have previously received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI
  • Cemiplimab-rwlc - NCI - National Cancer Institute
    FDA label information for this drug is available at DailyMed Use in Cancer Cemiplimab-rwlc is approved to treat adults with: Basal cell carcinoma (BCC) (a type of skin cancer) It is used in patients whose cancer has spread after treatment with hedgehog pathway inhibitor therapy or who cannot receive hedgehog pathway inhibitor therapy Cutaneous squamous cell carcinoma (a type of skin cancer
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • LIBTAYO (cemiplimab-rwlc) Label - Food and Drug Administration
    LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation (1)
  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • Cemiplimab-rwlc (Libtayo®) - OncoLink
    About Cemiplimab-rwlc (Libtayo®) The immune system works by creating antibodies, which are proteins that attach to antigens found on the surface of a cell The antibody “calls” the immune system to attack the cell it is attached to, resulting in the immune system killing the cell Monoclonal antibodies are created in a lab to attach to the antigens found on specific types of cancer cells
  • Libtayo (Cemiplimab-rwlc Injection): Side Effects, Uses . . .
    Drug Summary What Is Libtayo? Libtayo (cemiplimab -rwlc) is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation What Are Side Effects of Libtayo?
  • How do you know if LIBTAYO is working? Monitoring Your Response
    Learn how doctors and patients can determine if LIBTAYO (cemiplimab) is working Discover the key clinical tests, patient-reported symptoms, and important signs to monitor during immunotherapy
  • Libtayo (cemiplimab) dosing, indications, interactions . . .
    Medscape - Cutaneous squamous cell carcinoma and basal cell carcinoma dosing for Libtayo (cemiplimab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy lactation schedules, and cost information
  • Advanced squamous cell carcinoma: Treatment
    Radiation therapy: Radiation can target cancer cells in the skin, lymph nodes, or other areas of the body When a patient has advanced squamous cell skin cancer, radiation therapy is often used along with another treatment Immunotherapy: This type of treatment works with your body’s immune system to fight cancer





中文字典-英文字典  2005-2009